|
JP2011500823A
(ja)
*
|
2007-10-22 |
2011-01-06 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
|
|
US20100048524A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
|
JP5599783B2
(ja)
|
2008-05-30 |
2014-10-01 |
アムジエン・インコーポレーテツド |
Ｐｉ３キナーゼの阻害薬
|
|
NZ590688A
(en)
|
2008-08-05 |
2012-09-28 |
Daiichi Sankyo Co Ltd |
imidazo[4,5-b]pyridin-2-one derivatives
|
|
EP2385832B1
(en)
|
2009-01-08 |
2015-07-15 |
Curis, Inc. |
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
|
|
WO2010091306A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
|
EP2440058A4
(en)
*
|
2009-06-12 |
2012-11-21 |
Dana Farber Cancer Inst Inc |
MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
|
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
|
EP2937345B1
(en)
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
US20110319405A1
(en)
*
|
2010-06-28 |
2011-12-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
|
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
|
EP2678016B1
(en)
*
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
|
DK3111938T3
(da)
|
2011-04-01 |
2019-07-01 |
Curis Inc |
Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
|
|
AP2014007595A0
(en)
*
|
2011-09-30 |
2014-04-30 |
Kineta Inc |
Anti-viral compounds
|
|
JP6126615B2
(ja)
*
|
2011-11-11 |
2017-05-10 |
インテリカイン， エルエルシー |
キナーゼ阻害剤の組み合わせおよびそれらの使用
|
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
|
CA2867700A1
(en)
*
|
2012-03-23 |
2013-09-26 |
Memorial Sloan-Kettering Cancer Center |
Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
|
|
US9532982B2
(en)
*
|
2012-09-20 |
2017-01-03 |
Novartis Ag |
Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor and/an aromatase inhibitor
|
|
US10112927B2
(en)
|
2012-10-18 |
2018-10-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
US9073946B2
(en)
*
|
2013-01-15 |
2015-07-07 |
Kineta, Inc. |
Anti-viral compounds
|
|
WO2014158646A1
(en)
*
|
2013-03-13 |
2014-10-02 |
Dow Agrosciences Llc |
Improved process for the preparation of certain triaryl rhamnose carbamates
|
|
US20140275560A1
(en)
*
|
2013-03-13 |
2014-09-18 |
Dow Agrosciences Llc |
Preparation of 1,3-(substituted-diaryl)-1,2,4-triazoles and intermediates therefrom
|
|
EP2968370A4
(en)
|
2013-03-14 |
2016-09-21 |
Univ Maryland |
AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
|
|
EP3033088A4
(en)
|
2013-08-12 |
2017-03-08 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
|
JP6441910B2
(ja)
|
2013-09-30 |
2018-12-19 |
シャンハイ インリ ファーマシューティカル カンパニー リミティド |
縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
|
|
WO2015058140A1
(en)
|
2013-10-18 |
2015-04-23 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2015058126A1
(en)
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
SMT202400142T1
(it)
|
2014-01-13 |
2024-05-14 |
Aurigene Oncology Ltd |
Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
|
|
WO2015108881A1
(en)
|
2014-01-14 |
2015-07-23 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
WO2015108861A1
(en)
|
2014-01-14 |
2015-07-23 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
WO2015149001A1
(en)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
CN105130973B
(zh)
*
|
2014-05-26 |
2018-05-01 |
海南国瑞堂中药制药有限公司 |
5-吡啶基-2-氨基-苯并[d]噁唑衍生物及其制备方法和用途
|
|
CN106659758A
(zh)
|
2014-06-02 |
2017-05-10 |
儿童医疗中心有限公司 |
用于免疫调节的组合物和方法
|
|
AU2015371251B2
(en)
|
2014-12-23 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
CN107427521B
(zh)
|
2015-03-27 |
2021-08-03 |
达纳-法伯癌症研究所股份有限公司 |
细胞周期蛋白依赖性激酶的抑制剂
|
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
|
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
|
WO2017083835A1
(en)
*
|
2015-11-13 |
2017-05-18 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of tor complex 2 increases immunity against bacterial infection
|
|
US10722484B2
(en)
|
2016-03-09 |
2020-07-28 |
K-Gen, Inc. |
Methods of cancer treatment
|
|
CN107641118B
(zh)
*
|
2016-07-22 |
2020-11-06 |
爱科诺生物医药股份有限公司 |
具有细胞坏死抑制活性的化合物及其组合物和应用
|
|
WO2018017435A1
(en)
*
|
2016-07-22 |
2018-01-25 |
Accro Bioscience Inc. |
Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
|
|
CN120267671A
(zh)
*
|
2017-03-31 |
2025-07-08 |
奥锐金肿瘤有限公司 |
用于治疗血液病的化合物和组合物
|
|
CN109111464B
(zh)
*
|
2017-06-23 |
2021-02-26 |
爱科诺生物医药股份有限公司 |
一种具有细胞坏死抑制活性的杂环化合物
|
|
WO2018237370A1
(en)
*
|
2017-06-23 |
2018-12-27 |
Accro Bioscience Inc. |
Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
|
|
CA3067829A1
(en)
*
|
2017-06-23 |
2018-12-27 |
VelosBio Inc. |
Ror1 antibody immunoconjugates
|
|
ES2953025T3
(es)
|
2017-10-02 |
2023-11-07 |
1St Biotherapeutics Inc |
Compuestos de benzotiazol y métodos que usan los mismos para tratar trastornos neurodegenerativos
|
|
CN113194752A
(zh)
|
2018-06-01 |
2021-07-30 |
康奈尔大学 |
Pi3k相关疾病或病症的组合疗法
|
|
ES2988770T3
(es)
|
2018-06-08 |
2024-11-21 |
Ac Immune Sa |
Nuevos compuestos para diagnóstico
|
|
JP7590185B2
(ja)
|
2018-06-25 |
2024-11-26 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
|
|
JP7467423B2
(ja)
|
2018-09-11 |
2024-04-15 |
キュリス，インコーポレイテッド |
亜鉛結合部分を有するホスホイノシチド３－キナーゼ阻害剤との併用療法
|
|
CN109320511A
(zh)
*
|
2018-10-26 |
2019-02-12 |
广安凯特制药有限公司 |
一种高纯度帕博西尼中间体产品及其制备方法
|
|
WO2020140098A1
(en)
|
2018-12-28 |
2020-07-02 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
MX2021010122A
(es)
|
2019-02-22 |
2021-09-23 |
1St Biotherapeutics Inc |
Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
|
|
US20220160902A1
(en)
*
|
2019-03-07 |
2022-05-26 |
1ST Biotherapeutics, Inc. |
[18F]-Labeled Benzothiazole Derivative As PET Radiotracer
|
|
US10385046B1
(en)
|
2019-03-19 |
2019-08-20 |
1ST Biotherapeutics, Inc. |
Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
|
|
CN113631554B
(zh)
*
|
2019-03-28 |
2024-06-21 |
第一生物治疗股份有限公司 |
苯并噻唑化合物的药用盐、多晶型物及其制备方法
|
|
CN110256466A
(zh)
*
|
2019-07-31 |
2019-09-20 |
昆山迪安医学检验实验室有限公司 |
一种噻唑[5,4-b]-吡啶基生物活性化合物的制备方法及其抗肿瘤活性的检测
|
|
CN114981298B
(zh)
|
2019-12-12 |
2024-08-20 |
听治疗有限责任公司 |
用于预防和治疗听力损失的组合物和方法
|
|
US12570638B2
(en)
|
2020-05-20 |
2026-03-10 |
Sail Biomedicines, Inc. |
Fused imidazole derivatives as AHR antagonists
|
|
US20230234967A1
(en)
*
|
2020-05-28 |
2023-07-27 |
Senda Biosciences, Inc. |
Fused Azole Heterocycles as AHR Antagonists
|
|
JP7773233B2
(ja)
|
2020-08-21 |
2025-11-19 |
ファースト・バイオセラピューティクス・インコーポレイテッド |
Ｐｅｔ放射性トレーサとしての［１８ｆ］標識イミダゾピリジン誘導体
|
|
US12398156B2
(en)
*
|
2020-08-21 |
2025-08-26 |
1ST Biotherapeutics, Inc. |
Compounds for prevention or treatment of neurodegenerative disorders
|
|
TWI908894B
(zh)
*
|
2020-09-28 |
2025-12-21 |
南韓商福斯特生物股份有限公司 |
作為造血前驅細胞激酶１（ｈｐｋ１）抑制劑的吲唑及其用途
|
|
US12178821B2
(en)
|
2021-04-08 |
2024-12-31 |
Curis, Inc. |
Combination therapies for the treatment of cancer
|
|
JP2024529341A
(ja)
|
2021-07-15 |
2024-08-06 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
粒子が付着している細胞に関連する組成物および方法
|
|
CZ2023489A3
(cs)
*
|
2023-12-15 |
2025-05-28 |
Univerzita Hradec Králové |
1-(3-Chlor-4-hydroxyfenyl)-3-(6-((trifluormethyl)thio)benzo[d]thiazol-2-yl)močovina pro použití pro léčbu rakoviny
|
|
GB202415232D0
(en)
|
2024-10-16 |
2024-11-27 |
Nacamed As |
Composition
|